Luca Issi
Stock Analyst at RBC Capital
(2.07)
# 2,909
Out of 4,940 analysts
202
Total ratings
40.98%
Success rate
-8.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RGNX REGENXBIO | Maintains: Outperform | $21 → $17 | $7.46 | +127.88% | 10 | Aug 8, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $25 → $21 | $10.74 | +95.53% | 5 | Aug 8, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $40 → $38 | $17.21 | +120.80% | 9 | Aug 8, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $210 → $230 | $195.97 | +17.36% | 3 | Aug 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Sector Perform | $38 → $42 | $55.41 | -24.20% | 14 | Aug 5, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Sector Perform | $4 → $5 | $6.35 | -21.20% | 1 | Jul 30, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $25 → $23 | $11.24 | +104.63% | 3 | Jul 29, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $5 → $4 | $2.23 | +79.37% | 8 | May 15, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Outperform | $10 | $1.03 | +870.87% | 9 | May 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $21 → $18 | $23.85 | -24.53% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $28 | $25.47 | +9.93% | 17 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $4.41 | +353.51% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $330 | $435.00 | -24.14% | 27 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $105 → $95 | $15.05 | +531.23% | 7 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.44 | +354.13% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $12.56 | +35.35% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $7.81 | +66.45% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $5.53 | +532.91% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $17.17 | +51.47% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $40.84 | +71.40% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $56.80 | +23.24% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $14.12 | +69.97% | 6 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $32.37 | +76.09% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $45.78 | +46.35% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.20 | +81.82% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $27.39 | +181.12% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $8.11 | +85.07% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.71 | +718.71% | 5 | Aug 7, 2024 |
REGENXBIO
Aug 8, 2025
Maintains: Outperform
Price Target: $21 → $17
Current: $7.46
Upside: +127.88%
Intellia Therapeutics
Aug 8, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $10.74
Upside: +95.53%
Arrowhead Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $40 → $38
Current: $17.21
Upside: +120.80%
Ascendis Pharma
Aug 8, 2025
Maintains: Outperform
Price Target: $210 → $230
Current: $195.97
Upside: +17.36%
CRISPR Therapeutics AG
Aug 5, 2025
Maintains: Sector Perform
Price Target: $38 → $42
Current: $55.41
Upside: -24.20%
Fulcrum Therapeutics
Jul 30, 2025
Maintains: Sector Perform
Price Target: $4 → $5
Current: $6.35
Upside: -21.20%
Dyne Therapeutics
Jul 29, 2025
Maintains: Outperform
Price Target: $25 → $23
Current: $11.24
Upside: +104.63%
Adverum Biotechnologies
May 15, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.23
Upside: +79.37%
Allogene Therapeutics
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.03
Upside: +870.87%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $23.85
Upside: -24.53%
May 2, 2025
Maintains: Sector Perform
Price Target: $32 → $28
Current: $25.47
Upside: +9.93%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $4.41
Upside: +353.51%
Mar 21, 2025
Maintains: Outperform
Price Target: $310 → $330
Current: $435.00
Upside: -24.14%
Mar 19, 2025
Maintains: Outperform
Price Target: $105 → $95
Current: $15.05
Upside: +531.23%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.44
Upside: +354.13%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $12.56
Upside: +35.35%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $7.81
Upside: +66.45%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $5.53
Upside: +532.91%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $17.17
Upside: +51.47%
Feb 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $40.84
Upside: +71.40%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $56.80
Upside: +23.24%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $14.12
Upside: +69.97%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $32.37
Upside: +76.09%
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $45.78
Upside: +46.35%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.20
Upside: +81.82%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $27.39
Upside: +181.12%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $8.11
Upside: +85.07%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.71
Upside: +718.71%